(Q35892267)

11 August 2017

20 September 2017

The MEST score provides earlier risk prediction in lgA nephropathy (English)

1 reference

11 August 2017

The MEST score provides earlier risk prediction in IgA nephropathy (English)

1 reference

20 September 2017

0 references

8

Daniel C Cattran

2 references

11 August 2017

20 September 2017

3

Heather N Reich

2 references

11 August 2017

20 September 2017

Sean J Barbour

1

2 references

11 August 2017

20 September 2017

Gabriela Espino-Hernandez

2

2 references

11 August 2017

20 September 2017

Rosanna Coppo

4

2 references

11 August 2017

20 September 2017

Ian S D Roberts

5

2 references

11 August 2017

20 September 2017

John Feehally

6

2 references

11 August 2017

20 September 2017

Andrew M Herzenberg

7

2 references

11 August 2017

20 September 2017

Oxford Derivation, North American Validation and VALIGA Consortia

9

1 reference

11 August 2017

Oxford Derivation North American Validation and VALIGA Consortia

10

1 reference

11 August 2017

VALIGA

9

1 reference

20 September 2017

OXFORD DERIVATION AND NORTH AMERICAN VALIDATION

10

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 2016

1 reference

11 August 2017

28 October 2015

1 reference

20 September 2017

2 references

11 August 2017

20 September 2017

89

1 reference

11 August 2017

1

1 reference

11 August 2017

167-175

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2015.322

11 August 2017

0 references

cites work

The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Validation of the Oxford classification of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Remission of proteinuria improves prognosis in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Development and validation of a prediction rule using the Oxford classification in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Risk stratification of patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Predicting progression in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Validation of the Toronto formula to predict progression in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Predicting the risk for dialysis or death in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Histopathologic features aid in predicting risk for progression of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Dual effects of RAS blockade on blood pressure and podocyte function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

The use of the Oxford classification of IgA nephropathy to predict renal survival

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Several methods to assess improvement in risk prediction models: extension to survival analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Interpreting incremental value of markers added to risk prediction models

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.322

7 January 2021

Identifiers

DOI

10.1038/KI.2015.322

1 reference

release_l5vmrwlecfbs3iewpoe22p6lpe

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l5vmrwlecfbs3iewpoe22p6lpe

24 November 2022

mapped directly with Wikidata item

2 references

11 August 2017